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The microRNA-34s (miR-34s) have p53 response elements in their 5ʼ-ﬂanking regions and demonstrate 
tumor-suppressive functions.  In malignant pleural mesothelioma (MPM),  we previously reported that 
expression of miR-34b and miR-34c (miR-34b/c) was frequently downregulated by methylation in MPM 
cell lines and primary tumors.  The forced overexpression of miR-34b/c showed signiﬁcant antitumor 
eﬀects with the induction of apoptosis in MPM cells.  In this study,  we examined the in vivo antitumor 
eﬀects of miR-34b/c using adenovirus vector on MPM.  We subcutaneously transplanted NCI-H290,  a 
human MPM cell line,  into BALB/C mice and injected adenovirus vector expressing miR-34b/c,  
luciferase driven by the cytomegalovirus promoter (Ad-miR-34b/c or Ad-Luc),  or PBS control into 
tumors over 5mm in diameter.  A statistically signiﬁcant growth inhibition of the tumor volume was 
observed in the Ad-miR-34b/c group from day 6 onward compared to the Ad-Luc group.  The inhibi-
tion rate of Ad-miR-34b/c,  compared to the tumor volume treated with Ad-Luc,  was 58.6ｵ on day 10 
and 54.7ｵ on day13.  Our results indicate that adenovirus-mediated miR-34b/c gene therapy could be 
useful for the clinical treatment of MPM.
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alignant pleural mesothelioma (MPM) is a neo-
plasm with highly invasive and aggressive clini-
cal features,  and exposure to asbestos is strongly 
associated with its etiology [1].  Curative modalities 
such as radiotherapy,  conventional chemotherapy,  or 
molecular targeting therapy have not yet been estab-
lished for advanced MPM,  so the development of new 
treatments is urgently needed [2].
　 MicroRNAs (miRNAs) are a group of noncoding 
small RNAs that usually regulate their target mRNAs 
by posttranscriptional repression [3].  Recently,  there 
has been intensive research into the role of miRNAs 
in human malignant tumors because of the ability of 
individual miRNAs to regulate multiple genes impli-
cated in multiple pathways [4].  Similar to encoding 
genes,  some miRNAs have been classiﬁed as oncogenic 
or tumor-suppressive according to their eﬀects on 
cellular transformation [5].  Among the tumor-sup-
pressive miRNAs are the miRNA-34 family members 
(miR-34s) with p53 response elements in their 5ʼ-ﬂank-
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ing regions: the family includes miR-34a,  miR-34b and 
miR-34c [6-8].  These members are direct transcrip-
tional targets of p53 and constitute part of the p53 
tumor suppressor network regulating cell cycle arrest,  
apoptosis and senescence [6,  9].
　 In MPM,  mutations and deletions of the TP53 gene 
are rare [10,  11],  even though MPM is often associ-
ated with cell cycle alterations and anti-apoptosis,  
suggesting functional p53 deﬁciency [12].  We previ-
ously examined the methylation and expression status 
of miR-34s in thoracic malignancies such as lung can-
cer and MPM [13,  14].  We found that expression of 
miR-34b and miR-34c (miR-34b/c) was frequently 
downregulated by methylation in MPM cell lines and 
primary tumors,  and that forced overexpression of 
miR-34b/c,  but not of p53,  had a signiﬁcant antitu-
mor eﬀect that induced apoptosis in MPM cells in vitro 
[13].
　 In this study,  we used an adenovirus vector con-
taining miR-34b/c to examine the in vivo antitumor 
eﬀects of miR-34b/c on the MPM cell line NCI-H290 
(H290),  in which miR-34b and miR-34c expression is 
downregulated by methylation.
Materials and Methods
　 Cell line. H290,  a human MPM cell line,  was 
a kind gift from Dr. Adi F. Gazdar (Hamon Center for 
Therapeutic Oncology Research and Department of 
Pathology,  University of Texas Southwestern Medical 
Center at Dallas,  Dallas,  TX,  USA).
　 Adenovirus vectors carrying microRNA-34b/c  
and Luciferase. Adenovirus vector expressing 
miR-34b/c driven by cytomegalovirus (CMV) promoter 
(Ad-miR-34b/c) was generated by homologous recom-
bination and plaque puriﬁed.  Adenovirus vector 
expressing luciferase driven by CMV promoter 
(Ad-Luc) was used as a control vector [13,  15].  
Following the application manual Ver. 1.4 of AdEasyTM 
vector system (Agilent Technologies,  CA,  USA),  
Ad-miR-34b/c and Ad-Luc were ampliﬁed by infection 
with QBI-293A.  Adenovirus was puriﬁed with CsCl 
and viral suspension was titrated with O.D.  260nm 
[VP/mL].
　 Experimental animals. We used adult female 
mice (BALB/C nu/nu: 4 weeks) purchased from 
Charles River Laboratories Japan (Yokohama,  Japan).  
They were maintained in a speciﬁc pathogen-free 
environment with free access to food and water at the 
Department of Animal Reserves,  Shikata Laboratory,  
Advanced Science Research Center of Okayama 
University,  and allowed to adapt to their environment 
for more than one week before beginning the experi-
ments.  The animals were housed and handled in 
accordance with the Okayama University Animal 
Research Committee Guidelines.
　 Treatment protocol. H290 human MPM cells 
[1.0×107 in 50µl phosphate buﬀered saline (PBS)],  
mixed with 50µl of Matrigel (BD Biosciences,  San 
Jose,  CA,  USA),  were subcutaneously injected into 
the thighs of mice on both sides.  The tumors were 
permitted to grow to approximately 5mm in diameter 
and the mice were then randomly assigned to one of 
three treatment groups: (1) intratumoral injection of 
Ad-Luc,  (2) intratumoral injection of Ad-miR34b/c,  
or (3) intratumoral injection of PBS.  The injections 
were targeted to the center and periphery of each 
tumor mass to deliver the agent diﬀusely.  The ﬁrst 
day of vector administration was taken as day 0.  
Animals were observed 3 times per week for physical 
appearance,  activity levels and mortality patterns.
　 The transduction eﬃciency was checked after 
intratumoral vector injection.  Two mice in each of the 
3 groups were injected intratumorally with 100µl of 
the same concentration of Ad-Luc or Ad-miR-34b/c,  
or 100µl of PBS.  They were sacriﬁced on day 3 and the 
intratumoral expression of miR-34b/c was detected using 
quantitative real-time PCR as described previously.
　 To examine the antitumor eﬀects of Ad-miR-34b/c,  
we injected ﬁve mice per group with 100µl of Ad-Luc,  
Ad-miR-34b/c or PBS on day 0,  3 and 6.  The aver-
age concentration of Ad-Luc and Ad-miR-34b/c was 
1.86 (range,  1.25－2.16)×1011 viral particles/tumor in 
100µl buﬀer with reference to a previous report [16].
　 Tumor sizes were measured with vernier calipers 
and tumor volume was calcu-lated using the following 
formula: 3.14×1/2× (the shortest diameter)2× (the 
longest diameter).  The day of sacriﬁce was day 20 
after which tissues were frozen quickly by liquid 
nitrogen and stored at －80℃.  The body weight of 
each mouse was monitored using a sensitive balance 
during the entire study period.
　 Statistical analysis. Data were represented as 
mean ± SD.  Mann-Whitney U test was used to com-
pare data between groups.  The diﬀerences were con-
sidered statistically signiﬁcant at p＜0.05.
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Results
　 Conﬁrmation of miR-34b/c expression after 
treatment. We evaluated the intratumoral expres-
sion of miR-34b and miR-34c after injection in the 3 
groups of mice.  miR-34b and miR-34c expression in 
the Ad-miR-34b/c group was 27.9 and 19.2 times 
higher than in the PBS group,  respectively,  while 
that in the Ad-Luc group was the same as the PBS 
group (Fig.  1).  None of the mice died during the 
experiment in any of the treatment groups.
　 The growth inhibition of Ad-miR-34b/c treat-
ment on mouse H290 xenografts. Subsequently,  
we evaluated the growth inhibition of implanted tumors 
with Ad-miR-34b/c treatment.  There was no signiﬁ-
cant diﬀerence in the average tumor volume between 
the 3 groups on day 0: Ad-Luc 98.4±12.5mm3,  
Ad-miR-34b/c 97.1±14.9mm3,  and PBS 108.7±
7.1mm3.  Time course and tumor volume after treat-
ment are shown in Fig.  2.  A statistically signiﬁcant 
growth inhibition of tumor volume was observed in the 
Ad-miR-34b/c group compared to the Ad-Luc group 
from day 6 onward.  The inhibition rate of Ad-miR-
34b/c,  compared to the tumor volume treated with 
Ad-Luc,  was 58.6ｵ on day 10 and 54.7ｵ on day 13.  
Interestingly,  the tumor volume in the Ad-miR-34b/c 
group did not change from day 6 to day 10,  suggesting 
that Ad-miR-34b/c suppressed tumor growth during 
this period.  After day 10,  there was no diﬀerence in 
the rate of tumor growth between the Ad-miR-34b/c 
and Ad-Luc groups.
　 There was no signiﬁcant diﬀerence in the average 
body weight of the mice between the 3 groups 
throughout the experiment (Fig.  3).
Discussion
　 In this study,  we showed the direct antitumor 
eﬀect of miR-34b/c introduced by adenovirus vector 
on miR-34b/c silenced MPM cells in vivo.  To the best 
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Fig. 1　 The transduction eﬃciency after intratumoral adenovirus 
vector injection.  The intratumoral expression of miR-34b and miR-
34c was detected for 2 mice in each group with quantitative real-
time PCR.  miR-34b and miR-34c expression in the Ad-miR-34b/c 
group was higher than in the PBS group (p＜0.05),  while that in the 
Ad-Luc group was the same as the PBS group.  The expression in 
PBS group was considered the control.
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Fig. 2　 The growth inhibition of Ad-miR-34b/c treatment on 
mouse H290 xenografts.  The average tumor volume was calculated 
for 5 mice per group and the time course of tumor volumes after 
treatment is shown.  A statistically signiﬁcant growth inhibition of 
tumor volume was observed in the Ad-miR-34b/c group from day 6 
on compared to the Ad-Luc group (p＜0.05).
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Fig. 3　 The body weight in mice on day 0,  10 and 20 after each 
treatment.  There was no signiﬁcant diﬀerence in the average body 
weight of the mice between the 3 groups.
of our knowledge,  the in vivo therapeutic eﬀect of 
miR-34b/c has not previously been reported in any 
form of malignant disease.  In addition,  there have 
been no reports of miRNA use in MPM in vivo.  
However,  the therapeutic impact of miR-34a was 
previously shown following lentivirus-mediated trans-
fer.  Furthermore,  a lipid-based delivery of chemically 
synthesized miR-34a in lung cancer cells has also been 
demonstrated [17,  18].
　 Our previous study revealed the anti-proliferative 
eﬀect of Ad-miR-34b/c on 3 diﬀerent miR-34b/c 
methylated MPM cell lines (H28,  H290 and H2052).  
However,  stable xenografts could only be generated 
from H290 cells in the present study.  Although our 
previous study demonstrated the eﬀect of Ad-miR-
34b/c on MPM even in cell H2052 with preserved 
miR-34a expression,  the solo xenograft model here 
may be considered a limitation in this study.
　 The tumor growth curve in this study revealed that 
the antitumor eﬀect was observed until day 10,  4 days 
after the last injection of Ad-miR-34b/c.  There are a 
number of possible explanations for this,  including the 
heterogeneous tumor infection of Ad-miR-34b/c or the 
cytostatic eﬀect of Ad-miR-34b/c in vivo.
　 In addition,  miR-34b/c is known to enhance the 
eﬀects of radiation in vitro,  so its use in combination 
with chemotherapeutic agents or radiation might enhance 
the antitumor eﬀects of a single treatment [19].  This 
merits further investigation in future studies.
　 In summary,  we show that miR-34b/c suppresses 
MPM tumor growth in vivo,  which supports the ﬁnd-
ings of our previous in vitro study.  Preclinical studies 
such as this are an important part of the process of 
clinical application to assess target molecule and 
delivery systems in vivo.  Thus,  our study is relevant 
in that it shows the feasibility of miRNA MPM ther-
apy using a virus vector,  and suggests that Ad-miR-
34b/c in particular would be a promising therapeutic 
agent for MPM.
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